Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · IEX Real-Time Price · USD
10.50
+0.20 (1.94%)
May 24, 2024, 4:00 PM EDT - Market closed

Phathom Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018
Revenue
0.680000
Upgrade
Cost of Revenue
0.170000
Upgrade
Gross Profit
0.520000
Upgrade
Selling, General & Admin
117.9310162.7427.526.94
Upgrade
Research & Development
49.971.4472.3498.1520.37
Upgrade
Other Operating Expenses
000078.9
Upgrade
Operating Expenses
167.83172.44135.08125.67106.22
Upgrade
Operating Income
-167.31-172.44-135.08-125.67-106.22
Upgrade
Interest Expense / Income
41.9727.316.794.584.18
Upgrade
Other Expense / Income
-7.69-2.022.02-1.18144.74
Upgrade
Pretax Income
-201.59-197.72-143.88-129.07-255.13
Upgrade
Net Income
-201.59-197.72-143.88-129.07-255.13
Upgrade
Shares Outstanding (Basic)
5139373311
Upgrade
Shares Outstanding (Diluted)
5139373311
Upgrade
Shares Change
31.11%5.72%11.36%192.32%87.83%
Upgrade
EPS (Basic)
-3.93-5.05-3.89-3.88-22.45
Upgrade
EPS (Diluted)
-3.93-5.05-3.89-3.88-22.45
Upgrade
Free Cash Flow
-139.21-147.57-148.79-70.73-36.64
Upgrade
Free Cash Flow Per Share
-2.71-3.77-4.02-2.13-3.22
Upgrade
Gross Margin
75.51%----
Upgrade
Operating Margin
-24532.55%----
Upgrade
Profit Margin
-29558.94%----
Upgrade
Free Cash Flow Margin
-20412.61%----
Upgrade
EBITDA
-159.05-169.8-136.57-124.16-250.95
Upgrade
EBITDA Margin
-23320.97%----
Upgrade
Depreciation & Amortization
0.580.620.520.320.01
Upgrade
EBIT
-159.62-170.42-137.1-124.49-250.95
Upgrade
EBIT Margin
-23405.28%----
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).